HUP9900019A2 - Emberi CB2 receptor antagonista hatású indolszármazékok alkalmazása immunmoduláló gyógyszerek előállítására, új CB2 receptor agonista vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Emberi CB2 receptor antagonista hatású indolszármazékok alkalmazása immunmoduláló gyógyszerek előállítására, új CB2 receptor agonista vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9900019A2
HUP9900019A2 HU9900019A HUP9900019A HUP9900019A2 HU P9900019 A2 HUP9900019 A2 HU P9900019A2 HU 9900019 A HU9900019 A HU 9900019A HU P9900019 A HUP9900019 A HU P9900019A HU P9900019 A2 HUP9900019 A2 HU P9900019A2
Authority
HU
Hungary
Prior art keywords
receptor agonist
compounds
naphth
human
ring
Prior art date
Application number
HU9900019A
Other languages
English (en)
Inventor
Francis Barth
Malcolm R. Bell
Pierre Casellas
Christian Congy
Thomas E. D'ambra
Didier Oustric
Richard E. Philion
Murielle Rinaldi
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HUP9900019A2 publication Critical patent/HUP9900019A2/hu
Publication of HUP9900019A3 publication Critical patent/HUP9900019A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány emberi CB2 receptőr specifikűs agőnista vegyületekalkalmazására vőnatkőzik imműnmődűláló hatású gyógyszerekelőállítására. A vegyületek őlyan indőlszármazékők, amelyek az 1-es,3-as vagy 4-es helyzetben egy acilcsőpőrttal (-COR3 általánős képletűcsőpőrttal) helyettesítva vannak, ahől R8 jelentése halőgénatőmmal,alkil- vagy alkőxicsőpőrttal egyszeresen-négyszeresen szűbsztitűálvavan; vagy egy pőliciklűs, amely lehet naft-1-il-, naft-2-il-, 1,2,3,4-tetrahidrő-naft-1-il-, 1,2,3,4-tetrahidrő-naft-5-il-, antril-,benzőfűril-, benzőtien-2-il-, benzőtien-3-il-, 2-, 3-, 4- vagy 8-kinőlil-csőpőrt, amely pőliciklűsős csőpőrtők szűbsztitűálatlanők vagyegyszeresen vagy kétszeresen alkil-, alkőxi-, alkil-tiő-csőpőrttal,halőgénatőmmal, cianő-, hidrőxil-, triflűőr-metil- vagy imidazől-1-il-csőpőrttal szűbszitűálva vannak. A találmány egyes új vegyületekre ésaz új vegyületeket tartalmazó gyógyszerkészítményekre is vőnatkőzik. ŕ
HU9900019A 1995-06-21 1996-06-20 Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them HUP9900019A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9507438A FR2735774B1 (fr) 1995-06-21 1995-06-21 Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
HUP9900019A2 true HUP9900019A2 (hu) 1999-10-28
HUP9900019A3 HUP9900019A3 (en) 2001-03-28

Family

ID=9480236

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900019A HUP9900019A3 (en) 1995-06-21 1996-06-20 Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them

Country Status (30)

Country Link
US (1) US6013648A (hu)
EP (1) EP0833818B1 (hu)
JP (1) JP3417566B2 (hu)
KR (1) KR19990028272A (hu)
CN (1) CN1150166C (hu)
AT (1) ATE207054T1 (hu)
AU (1) AU717858B2 (hu)
BR (1) BR9608640A (hu)
CA (1) CA2225379A1 (hu)
CZ (1) CZ292630B6 (hu)
DE (1) DE69616056T2 (hu)
DK (1) DK0833818T3 (hu)
EE (1) EE9700345A (hu)
ES (1) ES2165986T3 (hu)
FR (1) FR2735774B1 (hu)
HK (1) HK1005093A1 (hu)
HU (1) HUP9900019A3 (hu)
IL (1) IL122637A0 (hu)
IS (1) IS4637A (hu)
MX (1) MX9710251A (hu)
NO (1) NO975989L (hu)
NZ (1) NZ312161A (hu)
PL (1) PL185598B1 (hu)
PT (1) PT833818E (hu)
RU (1) RU2200736C2 (hu)
SI (1) SI0833818T1 (hu)
SK (1) SK283660B6 (hu)
TR (1) TR199701660T1 (hu)
UA (1) UA67717C2 (hu)
WO (1) WO1997000860A1 (hu)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US20010009965A1 (en) * 1998-05-04 2001-07-26 Alexandros Makriyannis Novel analgesic and immunomodulatory cannabinoids
CA2340444A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
US7589220B2 (en) 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
MXPA02005101A (es) * 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
EP1702617A1 (en) * 1999-10-18 2006-09-20 The University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
EP1223808B1 (en) 1999-10-18 2007-03-07 The University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
AU2001264930A1 (en) * 2000-05-23 2001-12-03 The Regents Of The University Of California A novel treatment for cough
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002058636A2 (en) 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
AU2002320430A1 (en) 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
EP1406576B2 (en) * 2001-07-18 2011-06-29 Unilever PLC Hair and/or scalp treatment compositions
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
PL369952A1 (en) * 2001-11-14 2005-05-02 Schering Corporation Cannabinoid receptor ligands
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
EP1461027A4 (en) * 2001-12-07 2005-09-07 Univ Virginia Commonwealth TREATMENT OF NEOPLASIA
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
RU2337909C2 (ru) 2002-02-01 2008-11-10 Ф.Хоффманн-Ля Рош Аг Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
JPWO2003070277A1 (ja) 2002-02-19 2005-06-09 塩野義製薬株式会社 抗掻痒剤
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2004000807A1 (en) 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
JP2006511460A (ja) 2002-08-23 2006-04-06 ユニバーシティ オブ コネチカット 治療適応を持つケトカンナビノイド
MXPA05005512A (es) 2002-11-25 2005-07-25 Schering Corp Ligandos receptores canabinoides.
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
MX2007000015A (es) * 2004-06-22 2007-03-07 Schering Corp Ligandos de receptor de canabinoide.
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7560481B2 (en) 2004-12-21 2009-07-14 Abbott Laboratories Indoles are cannabinoid receptor ligands
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
FR2893615B1 (fr) 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN101448800A (zh) 2006-05-31 2009-06-03 艾博特公司 作为大麻素受体配体的新型化合物及其用途
CN101765594A (zh) 2007-03-28 2010-06-30 雅培制药有限公司 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008144360A1 (en) 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2933697B1 (fr) 2008-07-11 2010-08-13 Sanofi Aventis Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8188135B2 (en) 2008-09-16 2012-05-29 Abbott Laboratories Compounds as cannabinoid receptor ligands
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
FR2950055A1 (fr) 2009-09-17 2011-03-18 Sanofi Aventis Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique
WO2012024670A2 (en) * 2010-08-20 2012-02-23 University Of Washington Through Its Center For Commercialization Composition and methods for treating glioblastoma
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
WO2013106349A1 (en) * 2012-01-09 2013-07-18 The Board Of Trustees Of The University Of Arkansas Use of the aminoalkylindole jwh-073-m4 and related compounds as neutral cb1 recptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
US9656981B2 (en) 2012-07-20 2017-05-23 The Regents Of The University Of California Peripherally-acting cannabinoid receptor agonists for chronic pain
KR20150102511A (ko) * 2014-02-28 2015-09-07 주식회사 아세아텍 베일러용 드로우
CZ305780B6 (cs) * 2014-12-31 2016-03-09 Vysoká škola chemicko- technologická v Praze Derivát syntetického kanabinoidu, způsob jeho přípravy a použití
CZ306547B6 (cs) * 2014-12-31 2017-03-01 Vysoká škola chemicko - technologická v Praze Derivát syntetického kanabinoidu, způsob jeho přípravy a použití
CN109715152A (zh) * 2016-04-29 2019-05-03 柯巴斯医药有限公司 医治感染的方法
CN108794379A (zh) * 2017-04-26 2018-11-13 华东师范大学 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用
EP3743061A1 (en) 2018-01-22 2020-12-02 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
IL295374A (en) 2020-02-04 2022-10-01 Mindset Pharma Inc 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO77049A2 (ro) * 1980-08-08 1981-06-22 Institutul De Cercetari Chimico-Farmaceutice,Ro Derivati de 2-metil-3-etilindol si procedeu de preparare a acestora
RO90049A2 (ro) * 1984-12-25 1986-08-30 Centrala Industriala De Medicamente Cosmetice,Coloranti Si Lacuri,Ro Procedeu de preparare a clorhidratului hidrat de 1-(p-clorbenzoil)3-/2-(di-n-propilamino) etil/5-metoxi-2-metilindol
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
WO1997000860A1 (fr) 1997-01-09
EP0833818B1 (fr) 2001-10-17
HUP9900019A3 (en) 2001-03-28
HK1005093A1 (en) 1998-12-24
RU2200736C2 (ru) 2003-03-20
BR9608640A (pt) 1999-05-18
MX9710251A (es) 1998-03-31
FR2735774B1 (fr) 1997-09-12
FR2735774A1 (fr) 1996-12-27
PT833818E (pt) 2002-04-29
NO975989L (no) 1998-02-19
PL324185A1 (en) 1998-05-11
AU6363296A (en) 1997-01-22
CN1150166C (zh) 2004-05-19
AU717858B2 (en) 2000-04-06
SK283660B6 (sk) 2003-11-04
KR19990028272A (ko) 1999-04-15
NO975989D0 (no) 1997-12-19
SK173597A3 (en) 1998-11-04
JP3417566B2 (ja) 2003-06-16
CZ292630B6 (cs) 2003-11-12
CN1192732A (zh) 1998-09-09
US6013648A (en) 2000-01-11
SI0833818T1 (en) 2002-04-30
EE9700345A (et) 1998-06-15
ES2165986T3 (es) 2002-04-01
ATE207054T1 (de) 2001-11-15
UA67717C2 (en) 2004-07-15
TR199701660T1 (xx) 1998-04-21
DE69616056T2 (de) 2002-06-20
DK0833818T3 (da) 2002-02-11
NZ312161A (en) 2000-08-25
CA2225379A1 (en) 1997-01-09
EP0833818A1 (fr) 1998-04-08
IL122637A0 (en) 1998-08-16
IS4637A (is) 1997-12-19
PL185598B1 (pl) 2003-06-30
DE69616056D1 (de) 2001-11-22
CZ414397A3 (cs) 1998-07-15
JPH11507937A (ja) 1999-07-13

Similar Documents

Publication Publication Date Title
HUP9900019A2 (hu) Emberi CB2 receptor antagonista hatású indolszármazékok alkalmazása immunmoduláló gyógyszerek előállítására, új CB2 receptor agonista vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9901243A2 (hu) Kinazolinszármazékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP0002902A2 (hu) 3-Szubsztituált-3,4-dihidro-tieno[2,3-d]pirimidin-származékok és alkalmazásuk gyógyszerkészítmények előállítására
HUP9801602A2 (hu) Imidazo[1,2-a]piridin-származékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények, és alkalmazásuk
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
NL930018I2 (nl) (Piperidinylalkyl) chinazolinederivaten, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
HUP9802708A2 (hu) Biciklusos aminszármazékok, intermedierjeik, előállításuk, a vegyületeket hatóanyagként tartalmazó inszekticid, akaricid és nematocid készítmények és alkalmazásuk
NZ234854A (en) Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
HUP0001498A3 (en) Farnesyl transferase inhibiting 1,8-annelated imidazolyl-quinolinone derivatives, their intermediates, pharmaceutical compositions thereof and process for their preparation
HUP9801599A2 (hu) Alfa1L-agonista imidazolinszármazékok alkalmazása inkontinencia kezelésére szolgáló gyógyszerkészítmények előállítására, új imidazolin-származékok és eljárás ezek előállítására
HUP9901244A3 (en) 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP0500870A2 (hu) Nitrogéntartalmú heterociklusos melanokortin receptor ligandumok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9801948A2 (hu) Oxigéntartalmú heterociklusos csoportokat tartalmazó szulfonamidok és azokat tartalmazó gyógyszerkészítmények
WO1991019475A1 (en) Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene d¿4?
HUP9802679A2 (hu) Multidrog rezisztencia hatással rendelkező tetralinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
ATE156804T1 (de) Ethanolamin-derivate mit sympathomimetischer und anti-pollakiuria wirkung
PT1117661E (pt) Derivados de propanolaminas substituidos com heterociclos, procedimento para a sua preparacao, farmacos contendo estes compostos e a sua aplicacao
NO913008D0 (no) Fremgangsmaate for fremstilling av fenylacetamid-derivater.
MY118569A (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
PL288409A1 (en) Method of obtaining novel derivatives of 4-phenyl-4-piperidinecarboxyamide
AU8508782A (en) 1-aryl 2-aminomethyl cyclopropane carboxylates
HUP0300562A2 (hu) [(Hidroxi-fenil)-piperazinil-metil]-benzamid-származékok fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX9207620A (es) Derivados de bencenmetanamina a-substituidos y procedimiento para su preparacion.
AU2654692A (en) Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees